ClinicalTrials.gg
CompletedNCT06580587Updated Apr 16, 2026

A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)

A Phase 1 interventional study of MK-8527 in Healthy and HIV Pre-exposure Prophylaxis, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this study is to learn how MK-8527 moves through the healthy person's body over time. Researchers will measure for the amount of MK-8527 in breast milk that the baby will receive at many time points.

02

Conditions studied

  • Healthy
  • HIV Pre-exposure Prophylaxis
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is at least 6 weeks postpartum at the time of administration of study intervention, following the delivery of a healthy singleton neonate
  • Is willing and able to express breast milk at least twice daily for at least 120 hours after enrollment
  • Is willing to discontinue breastfeeding from the time of administration of study intervention until at least 6 weeks following the administration of study intervention. This includes the avoidance of both directly breastfeeding and the administration of breast milk pumped during the above-specified time frame to the infant. Is willing to confirm with the site that the infant is able to bottle feed (breast milk) prior to Day 1 and that alternative nutrition (i.e., previously stored breast milk or infant formula) is available for feeding the infant through the 6-week post dose period

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, psychiatric, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Had mastitis within 30 days prior to administration of study drug
  • Has a positive pregnancy test at the time of screening or prior to treatment allocation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    MK-8527

    Participants receive single oral dose of MK-8527 on Day 1

    Drug: MK-8527

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to 120 hours (AUC0-120hrs) After Administration of a Single Oral Dose of MK-8527 in Breast Milk

    Breast milk samples will be collected to determine the AUC0-120hrs after administration of a single oral dose of MK-8527.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  2. Maximum Breast Milk Concentration (Cmax) After Administration of a Single Oral Dose of MK-8527

    Breast milk samples will be collected to determine the Cmax after administration of a single oral dose of MK-8527.

    Time frame: Predose and at designated timepoints up to 21 days postdose

  3. Time to Maximum Breast Milk Concentration (Tmax) After Administration of a Single Oral Dose of MK-8527

    Breast milk samples will be collected to determine the Tmax after administration of a single oral dose of MK-8527.

    Time frame: Predose and at designated timepoints up to 21 days postdose

Secondary outcomes

  1. Mean Concentration of MK-8527 in Breast Milk After Administration of a Single Oral Dose

    Breast milk samples will be collected to determine the mean concentration of MK-8527.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  2. Amount Excreted in Breast Milk From Time Zero to 120 Hours (Ae0-120hrs) After Administration of a Single Oral Dose of MK-8527

    Breast milk samples will be collected to determine the Ae0-120hrs after administration of a single oral dose of MK-8527.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  3. Area Under the Concentration-Time Curve from Time 0 to 120 hours (AUC0-120hrs) After Administration of a Single Oral Dose of MK-8527 in Blood

    Blood samples will be collected to determine AUC0-120hrs after administration of a single oral dose of MK-8527.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  4. Area Under the Concentration-Time Curve from Time 0 to Time-Infinity (AUC0-Inf) After Administration of a Single Oral Dose of MK-8527 in Blood

    Blood samples will be collected to determine AUC0-inf after administration of a single oral dose of MK-8527.

    Time frame: Predose and at designated timepoints up to 21 days postdose

  5. Maximum Blood Concentration (Cmax) After Administration of a Single Oral Dose of MK-8527

    Blood samples will be collected to determine the Cmax after administration of a single oral dose of MK-8527.

    Time frame: Predose and at designated timepoints up to 21 days postdose

  6. Time to Maximum Blood Concentration (Tmax) After Administration of a Single Oral Dose of MK-8527

    Blood samples will be collected to determine the Tmax after administration of a single oral dose of MK-8527.

    Time frame: Predose and at designated timepoints up to 21 days postdose

  7. Area Under the Concentration-Time Curve from Time 0 to 120hours (AUC0-120hrs) After Administration of a Single Oral Dose of MK-8527 in Plasma

    Plasma samples will be collected to determine AUC0-120hrs after administration of a single oral dose of MK-8527.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  8. Area Under the Concentration-Time Curve from Time 0 to Time-Infinity (AUC0-Inf) After Administration of a Single Oral Dose of MK-8527 in Plasma

    Plasma samples will be collected to determine AUC0-inf.

    Time frame: Predose and at designated timepoints up to 7 days postdose

  9. Maximum Plasma Concentration (Cmax) After Administration of a Single Oral Dose of MK-8527

    Plasma samples will be collected to determine the Cmax after administration of a single oral dose of MK-8527.

    Time frame: Predose and at designated timepoints up to 7 days postdose

  10. Time to Maximum Plasma Concentration (Tmax) After Administration of a Single Oral Dose of MK-8527

    Plasma samples will be collected to determine the Tmax after administration of a single oral dose of MK-8527.

    Time frame: Predose and at designated timepoints up to 7 days postdose

  11. Ratio of MK-8527 in Breast Milk to Blood After Administration of a Single Dose of MK-8527

    Ratio of MK-8527 in breast milk to blood will be used to estimate dose of MK-8527.

    Time frame: At designated timepoints up to 120 hours postdose

  12. Ratio of MK-8527 in Breast Milk to Plasma After Administration of a Single Oral Dose

    Ratio of MK-8527 in breast milk to plasma will be used to estimate dose of MK-8527.

    Time frame: At designated timepoints up to 120 hours postdose

07

Study locations

2 sites
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)
    Springfield, Missouri 65802, United States
  • University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0001)
    Pittsburgh, Pennsylvania 15213, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Mar 2026, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Aug 30, 2024
StartActual
Apr 15, 2025
Primary completionActual
Mar 27, 2026
CompletionActual
Mar 27, 2026
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06580587
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Apr 15, 2025
Primary completion
Mar 27, 2026
Completion
Mar 27, 2026
Last update
Apr 16, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alimatravir

Start the discussion